Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
The American Society of Clinical Oncology (ASCO) convened a subcommittee to develop recommendations on improving the evidence base for treating older adults with cancer in response to a critical need identified by the Institute of Medicine. Older adults experience the majority of cancer diagnoses and deaths and make up the majority of cancer survivors. Older adults are also the fastest growing segment of the US population. However, the evidence base for treating this population is sparse, because older adults are underrepresented in clinical trials, and trials designed specifically for older adults are rare. The result is that clinicians have less evidence on how to treat older adults, who represent the majority of patients with cancer. Clinicians and patients are forced to extrapolate from trials conducted in younger, healthier populations when developing treatment plans. This has created a dearth of knowledge regarding the risk of toxicity in the average older patient and about key end points of importance to older adults. ASCO makes five recommendations to improve evidence generation in this population: (1) Use clinical trials to improve the evidence base for treating older adults with cancer, (2) leverage research designs and infrastructure for generating evidence on older adults with cancer, (3) increase US Food and Drug Administration authority to incentivize and require research involving older adults with cancer, (4) increase clinicians' recruitment of older adults with cancer to clinical trials, and (5) use journal policies to improve researchers' reporting on the age distribution and health risk profiles of research participants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
Hurria, A., Togawa, K., Mohile, S. G., Owusu, C., Klepin, H. D., Gross, C. P., Lichtman, S. M., Gajra, A., Bhatia, S., Katheria, V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7625 · Cited by 1,841 · cited 1×
“benefit or not from treatment, because factors other than age are crucial to making these assessments.(46-53) Clinical trials conducted by”
Self-citationUnderstanding the Treatment Preferences of Seriously Ill Patients
Fried, T. R., Bradley, E. H., Towle, V. R., & Allore, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012528 · Cited by 1,522
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,350
Extermann, M., Boler, I., Reich, R. R., Lyman, G. H., Brown, R. H., DeFelice, J., Levine, R. M., Lubiner, E. T., Reyes, P., Schreiber, F. J., et al. (2012) · Cancer · doi:10.1002/cncr.26646 · Cited by 1,143
Van Spall, H. G. C., Toren, A., Kiss, A., & Fowler, R. A. (2007) · JAMA · doi:10.1001/jama.297.11.1233 · Cited by 1,055
Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis
Levit, L. A., Balogh, E. P., Nass, S. J., & Ganz, P. A. (2014) · Cited by 1,040
Self-citationParticipation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Lewis, J. H., Kilgore, M. L., Goldman, D. P., Trimble, E. L., Kaplan, R., Montello, M. J., Housman, M. G., & Escarce, J. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.010 · Cited by 1,031
Juliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., & Höglund, M. (2009) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 987
Cited by
Mohile, S. G., Dale, W., Somerfield, M. R., Schonberg, M. A., Boyd, C. M., Burhenn, P. S., Canin, B., Cohen, H. J., Holmes, H. M., Hopkins, J. O., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8687 · Cited by 1,479
Self-citationBluethmann, S. M., Mariotto, A. B., & Rowland, J. H. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0133 · Cited by 1,146
“, especially those aged 85 years and older) compared with other older adults, and how this burden may change over time (8).”
BackgroundLi, D., Sun, C.-L., Kim, H., Soto-Perez-de-Celis, E., Chung, V., Koczywas, M., Fakih, M., Chao, J., Cabrera Chien, L., Charles, K., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4158 · Cited by 481
Self-citationSedrak, M. S., Freedman, R. A., Cohen, H. J., Muss, H. B., Jatoi, A., Klepin, H. D., Wildes, T. M., Le‐Rademacher, J. G., Kimmick, G. G., Tew, W. P., et al. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21638 · Cited by 471
Self-citationSoto-Perez-de-Celis, E., Li, D., Yuan, Y., Lau, Y. M., & Hurria, A. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30348-6 · Cited by 400
Self-citationCancer statistics for adults aged 85 years and older, 2019
DeSantis, C. E., Miller, K. D., Dale, W., Mohile, S. G., Cohen, H. J., Leach, C. R., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21577 · Cited by 370
Self-citationMohile, S. G., Epstein, R. M., Hurria, A., Heckler, C. E., Canin, B., Culakova, E., Duberstein, P., Gilmore, N., Xu, H., Plumb, S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4728 · Cited by 301
Self-citationBiganzoli, L., Battisti, N. M. L., Wildiers, H., McCartney, A., Colloca, G., Kunkler, I. H., Cardoso, M.-J., Cheung, K.-L., de Glas, N. A., Trimboli, R. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30741-5 · Cited by 298
Self-citationComorbidity in older adults with cancer
Williams, G. R., Mackenzie, A., Magnuson, A., Olin, R., Chapman, A., Mohile, S., Allore, H., Somerfield, M. R., Targia, V., Extermann, M., et al. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2015.12.002 · Cited by 297
Self-citationEfficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218
The state of Cancer Care in America, 2017: a report by the American Society of Clinical Oncology
The American Society of Clinical Oncology (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.020743 · Cited by 204
Mohile, S. G., Dale, W., Somerfield, M. R., & Hurria, A. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00180 · Cited by 187
Self-citationGrossi, F., Crinò, L., Logroscino, A., Canova, S., Delmonte, A., Melotti, B., Proto, C., Gelibter, A., Cappuzzo, F., Turci, D., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.015 · Cited by 111
Harnessing Real-World Evidence to Advance Cancer Research
Tang, M., Pearson, S.-A., Simes, R. J., & Chua, B. H. (2023) · Current Oncology · doi:10.3390/curroncol30020143 · Cited by 88
Experiences of healthcare providers of older adults with cancer during the COVID-19 pandemic
Krok-Schoen, J. L., Pisegna, J. L., BrintzenhofeSzoc, K., MacKenzie, A. R., Canin, B., Plotkin, E., Boehmer, L. M., & Shahrokni, A. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.09.021 · Cited by 27
Metadata
- Authors
- Hurria, A., Levit, L. A., Dale, W., Mohile, S. G., Muss, H. B., Fehrenbacher, L., Magnuson, A., Lichtman, S. M., Bruinooge, S. S., Soto-Perez-de-Celis, E., Tew, W. P., Postow, M. A., & Cohen, H. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-10
- Volume
- 33
- Issue
- 32
- Pages
- 3826-3833
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149386818
- Cited by
- 419
- References
- 69
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.